CRA was hired by a biotech company with a new product in development for oncology. The main objective was to quantitatively understand current treatment dynamics and future market opportunity. We evaluated multiple data sources and developed patient flow and market map for two tumor types, using a patient-level claim data. We further created competitive landscape assessment and identified target intervention points for each scenario, in collaboration with the client. Research was conducted for both US and EU5 to size the global commercial opportunity.
Psoriasis patient source of business for major IL-23 agents
CRA analytics insight A higher proportion of Tremfya patients, versus Skyrizi patients, were previously treated with an IL-17 agent (i.e., Cosentyx or Taltz)...